Using laser treatment to manage glaucoma in patients receiving a Boston keratoprosthesis
The Role of Transscleral Cyclophotocoagulation in Patients Undergoing a Boston Keratoprosthesis
This study is testing a laser treatment to see if it can help manage glaucoma in patients who have received an artificial cornea to improve their vision.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) Academic / other |
| Locations | 1 site (Montreal, Quebec) |
| Trial ID | NCT04232982 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of transscleral cyclophotocoagulation (TS-CPC) in patients undergoing a Boston keratoprosthesis, an artificial cornea used for vision restoration. The study aims to address the high prevalence of glaucoma in these patients, which can lead to significant vision loss post-surgery. By employing advanced laser techniques, the trial seeks to reduce intra-ocular pressure and improve glaucoma management in this specific patient population. Participants will be monitored for their response to the laser treatment and its impact on their overall eye health.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients who are scheduled to receive a Boston keratoprosthesis and can provide informed consent.
Not a fit: Patients who have had prior glaucoma surgeries or those with severe ocular surface disease or terminal glaucoma may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve glaucoma management and preserve vision in patients receiving a Boston keratoprosthesis.
How similar studies have performed: While the use of TS-CPC has been explored in other contexts, this specific application in conjunction with the Boston keratoprosthesis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults patients * Able to give an informed consent * Capable of being followed during the study * Candidate for the Boston keratoprosthesis type I Exclusion Criteria: * Patients younger than 18 years old or older than 80 years old * Unable to give an informed consent * Participating to another interventional glaucoma study * Patients who received a glaucoma surgery or procedure (glaucoma drainage device or TS-CPC treatment) 3 months before their initial visit. * Unable to wear a therapeutic contact lens secondary to eyelid malformation * Severe Ocular surface Disease with keratinization * Intra-ocular tumor * Terminal Glaucoma * Phthisis bulbi * Ocular albinism
Where this trial is running
Montreal, Quebec
- Centre Hospitalier de l'Université de Montréal (CHUM) — Montreal, Quebec, Canada (Recruiting)
Study contacts
- Principal investigator: Marie-Claude Robert, MD, MSc — Ophthalmology Department, Centre Hospitalier de l'Université de Montreal
- Study coordinator: Marie-Catherine Thessier, MSc
- Email: marie-catherine.tessier.chum@ssss.gouv.qc.ca
- Phone: 514 890-8000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.